ReviewThe journal of allergy and clinical immunology. In practice2023
Refractory Anaphylaxis: A New Entity for Severe Anaphylaxis.
Review in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Successful treatment of refractory anaphylactic shock with angiotensin II: A case report.European journal of anaesthesiology and intensive care · 2026Article
- Anaphylaxis: Clinical Criteria, Severity, and Clinical Courses.Immunology and allergy clinics of North America · 2026Review
- Pediatric anaphylaxis in the emergency department: Performances of dynamic tryptase measurement.The journal of allergy and clinical immunology. Global · 2025Article
- Anaphylaxis: Definition and criteria.Journal of food allergy · 2024Article
- Management of Refractory Anaphylaxis: An Overview of Current Guidelines.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024Review
- Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee.The World Allergy Organization journal · 2024Review
- The bradykinin-forming cascade in anaphylaxis and ACE-inhibitor induced angioedema/airway obstruction.Frontiers in allergy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 8 countries.
Funding
Abstract
Anaphylaxis reactions lie on a spectrum of severity, ranging from relatively mild lower respiratory involvement (depending on the definition of anaphylaxis used) to more severe reactions that are refractory to initial treatment with epinephrine and may rarely cause death. A variety of grading scales exist to characterize severe reactions, but there is a lack of consensus about the optimal approach to define severity. More recently, a new entity called refractory anaphylaxis (RA) has emerged in the literature, characterized by the persistence of anaphylaxis despite initial epinephrine treatment. However, slightly different definitions have been proposed to date. In this Rostrum, we review these definitions as well as data relating to epidemiology, elicitors, risk factors, and management of RA. We propose a need to align the different definitions for RA, to improve epidemiological surveillance, advance our understanding of the pathophysiology of RA, and optimize management strategies to reduce morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.